Getinge (OTCMKTS:GNGBY) Sets New 12-Month High – Should You Buy?

Getinge (OTCMKTS:GNGBY)’s share price hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $25.9950 and last traded at $25.9950, with a volume of 249 shares traded. The stock had previously closed at $25.51.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GNGBY. Pareto Securities cut shares of Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 24th. UBS Group started coverage on shares of Getinge in a report on Wednesday, September 2nd. They issued a “hold” rating on the stock. Zacks Research downgraded Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 17th. Finally, Nordea Equity Research downgraded shares of Getinge from a “buy” rating to a “hold” rating in a research report on Monday, August 31st. Four research analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Getinge Price Performance

The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.74 and a current ratio of 1.31. The firm’s fifty day simple moving average is $25.02 and its 200 day simple moving average is $22.52. The firm has a market cap of $7.08 billion, a P/E ratio of 24.76 and a beta of 0.95.

Getinge (OTCMKTS:GNGBY) last posted its quarterly earnings data on Friday, July 17th. The company reported $0.38 earnings per share for the quarter. Getinge had a net margin of 7.81% and a return on equity of 11.12%. The company had revenue of $894.87 million for the quarter. As a group, analysts forecast that Getinge will post 1.38 earnings per share for the current year.

Getinge Company Profile

Getinge AB is a Swedish medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support surgical procedures, intensive care, infection prevention and the manufacture of pharmaceuticals and other medical products.

The company’s portfolio includes operating room and surgical workflow systems, anesthesia and ventilation equipment, intensive care solutions, cardiovascular devices, sterilization and disinfection systems, and equipment for laboratories and pharmaceutical production.